34
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In idiopathic pulmonary fibrosis (IPF), the fibroblast focus is a key histological feature representing active fibroproliferation. On standard 2D pathologic examination, fibroblast foci are considered small, distinct lesions, although they have been proposed to form a highly interconnected reticulum as the leading edge of a “wave” of fibrosis. Here, we characterized fibroblast focus morphology and interrelationships in 3D using an integrated micro-CT and histological methodology. In 3D, fibroblast foci were morphologically complex structures, with large variations in shape and volume (range, 1.3 × 10 4 to 9.9 × 10 7 μm 3). Within each tissue sample numerous multiform foci were present, ranging from a minimum of 0.9 per mm 3 of lung tissue to a maximum of 11.1 per mm 3 of lung tissue. Each focus was an independent structure, and no interconnections were observed. Together, our data indicate that in 3D fibroblast foci form a constellation of heterogeneous structures with large variations in shape and volume, suggesting previously unrecognized plasticity. No evidence of interconnectivity was identified, consistent with the concept that foci represent discrete sites of lung injury and repair.

          Related collections

          Most cited references43

          • Record: found
          • Abstract: found
          • Article: not found

          Fiji: an open-source platform for biological-image analysis.

          Fiji is a distribution of the popular open-source software ImageJ focused on biological-image analysis. Fiji uses modern software engineering practices to combine powerful software libraries with a broad range of scripting languages to enable rapid prototyping of image-processing algorithms. Fiji facilitates the transformation of new algorithms into ImageJ plugins that can be shared with end users through an integrated update system. We propose Fiji as a platform for productive collaboration between computer science and biology research communities.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management

            American Journal of Respiratory and Critical Care Medicine, 183(6), 788-824
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

              Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
                Bookmark

                Author and article information

                Journal
                101676073
                44864
                JCI Insight
                JCI Insight
                JCI insight
                2379-3708
                28 May 2016
                21 April 2016
                01 June 2016
                : 1
                : 5
                : e86375
                Affiliations
                [1 ]Academic Unit of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
                [2 ]National Institute for Health Research Respiratory Biomedical Research Unit, University Hospital Southampton, Southampton, United Kingdom
                [3 ]Department of Histopathology, St. Vincent’s University Hospital, Elm Park, Dublin, Ireland
                [4 ]μ-VIS X-ray Imaging Centre, Faculty of Engineering and the Environment, University of Southampton, Southampton, United Kingdom
                [5 ]Clinical Immunology, Department of Medicine, Padua University, Padua, Italy
                [6 ]Department of Cellular Pathology, University Hospital Southampton, Southampton, United Kingdom
                [7 ]Department of Cardiothoracic Surgery, University Hospital Southampton, Southampton, United Kingdom
                [8 ]Mater Misericordiae University Hospital, Dublin, Ireland
                [9 ]School of Medicine and Medical Science, University College Dublin, Dublin, Ireland
                [10 ]Institute for Life Sciences, University of Southampton, Southampton, United Kingdom
                [11 ]Department of Radiology, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College, London, United Kingdom
                [12 ]Department of Histopathology, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College, London, United Kingdom
                [13 ]Department of Medicine, National Jewish Health, Denver, Colorado, USA
                Author notes
                Address correspondence to: Mark Jones, Academic Unit of Clinical and Experimental Sciences, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, United Kingdom. Phone: 44.2381.203308; Mark.Jones@ 123456soton.ac.uk

                Authorship note: A. Fabre and P. Schneider contributed equally to this work.

                Article
                NIHMS790182
                10.1172/jci.insight.86375
                4889020
                27275013
                5a240bfa-0a31-46bf-ad7d-2b4814f67730

                This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                Categories
                Article

                Comments

                Comment on this article